-
公开(公告)号：US08304546B2
公开(公告)日：2012-11-06
申请号：US12668164
申请日：2009-12-04
申请人： Kenji Otsubo , Takahito Yamauchi , Yuji Ochi
发明人： Kenji Otsubo , Takahito Yamauchi , Yuji Ochi
IPC分类号： C07D215/38
CPC分类号： C07D221/06 , C07D215/18 , C07D215/22 , C07D215/233 , C07D215/26 , C07D215/28 , C07D215/40 , C07D215/48 , C07D221/10 , C07D221/16 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D413/14 , C07D471/04 , C07D491/04 , C07F9/60 , C07F9/65583 , C07F9/6561 , C07H19/04
摘要： The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): wherein: R1 represents hydrogen or the like; R2 represents hydrogen or the like; R3 represents substituted or unsubstituted phenyl or the like; R4 represents halogen or the like; R5 represents hydrogen or the like; R6 represents hydrogen or the like; and R7 represents hydrogen or the like.
摘要翻译： 本发明提供了抑制帕金森病慢性进展或保护多巴胺神经元免受疾病病因的喹诺酮化合物，从而抑制神经功能障碍的进展，从而延长使用L-多巴的时间，同时也改善神经元功能 ; 本发明的喹诺酮化合物由式（1）表示：其中：R1表示氢等; R2表示氢等; R3表示取代或未取代的苯基等; R4表示卤素等; R5表示氢等; R6表示氢等; 并且R 7表示氢等。
-
公开(公告)号：US20110269705A1
公开(公告)日：2011-11-03
申请号：US12668164
申请日：2009-12-04
申请人： Kenji Otsubo , Takahito Yamauchi , Yuji Ochi
发明人： Kenji Otsubo , Takahito Yamauchi , Yuji Ochi
IPC分类号： A61K31/706 , A61K31/473 , C07D407/04 , C07D409/04 , C07D413/06 , A61K31/5377 , C07D413/14 , A61K31/553 , C07F9/60 , A61K31/675 , C07D401/14 , A61K31/496 , A61K31/397 , C07H19/048 , A61P3/10 , A61P35/00 , A61P9/00 , A61P25/18 , A61P25/00 , A61P25/24 , A61P13/12 , C07D215/233
CPC分类号： C07D221/06 , C07D215/18 , C07D215/22 , C07D215/233 , C07D215/26 , C07D215/28 , C07D215/40 , C07D215/48 , C07D221/10 , C07D221/16 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D413/14 , C07D471/04 , C07D491/04 , C07F9/60 , C07F9/65583 , C07F9/6561 , C07H19/04
摘要： The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): wherein: R1 represents hydrogen or the like; R2 represents hydrogen or the like; R3 represents substituted or unsubstituted phenyl or the like; R4 represents halogen or the like; R5 represents hydrogen or the like; R6 represents hydrogen or the like; and R7 represents hydrogen or the like.
摘要翻译： 本发明提供了抑制帕金森病慢性进展或保护多巴胺神经元免受疾病病因的喹诺酮化合物，从而抑制神经功能障碍的进展，从而延长使用L-多巴的时间，同时也改善神经元功能 ; 本发明的喹诺酮化合物由式（1）表示：其中：R1表示氢等; R2表示氢等; R3表示取代或未取代的苯基等; R4表示卤素等; R5表示氢等; R6表示氢等; 并且R 7表示氢等。
-
公开(公告)号：USRE45108E1
公开(公告)日：2014-09-02
申请号：US14038862
申请日：2013-09-27
申请人： Kenji Otsubo , Takahito Yamauchi , Yuji Ochi
发明人： Kenji Otsubo , Takahito Yamauchi , Yuji Ochi
IPC分类号： C07D221/06 , C07D215/38 , C07D215/233 , C07D215/18
CPC分类号： C07D221/06 , C07D215/18 , C07D215/22 , C07D215/233 , C07D215/26 , C07D215/28 , C07D215/40 , C07D215/48 , C07D221/10 , C07D221/16 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D413/14 , C07D471/04 , C07D491/04 , C07F9/60 , C07F9/65583 , C07F9/6561 , C07H19/04
摘要： The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): wherein: R1 represents hydrogen or the like; R2 represents hydrogen or the like; R3 represents substituted or unsubstituted phenyl or the like; R4 represents halogen or the like; R5 represents hydrogen or the like; R6 represents hydrogen or the like; and R7 represents hydrogen or the like.
摘要翻译： 本发明提供了抑制帕金森病慢性进展或保护多巴胺神经元免受疾病病因的喹诺酮化合物，从而抑制神经功能障碍的进展，从而延长使用L-多巴的时间，同时也改善神经元功能 ; 本发明的喹诺酮化合物由式（1）表示：其中：R1表示氢等; R2表示氢等; R3表示取代或未取代的苯基等; R4表示卤素等; R5表示氢等; R6表示氢等; 并且R 7表示氢等。
-
公开(公告)号：US08592593B2
公开(公告)日：2013-11-26
申请号：US13616740
申请日：2012-09-14
申请人： Kenji Otsubo , Takahito Yamauchi , Yuji Ochi
发明人： Kenji Otsubo , Takahito Yamauchi , Yuji Ochi
IPC分类号： C07D215/38
CPC分类号： C07D221/06 , C07D215/18 , C07D215/22 , C07D215/233 , C07D215/26 , C07D215/28 , C07D215/40 , C07D215/48 , C07D221/10 , C07D221/16 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D413/14 , C07D471/04 , C07D491/04 , C07F9/60 , C07F9/65583 , C07F9/6561 , C07H19/04
摘要： The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): wherein: R1 represents hydrogen or the like; R2 represents hydrogen or the like; R3 represents substituted or unsubstituted phenyl or the like; R4 represents halogen or the like; R5 represents hydrogen or the like; R6 represents hydrogen or the like; and R7 represents hydrogen or the like.
-
公开(公告)号：US08269011B2
公开(公告)日：2012-09-18
申请号：US12599003
申请日：2008-06-06
申请人： Kenji Otsubo , Yuji Ochi , Masami Nakai , Atsushi Mori
发明人： Kenji Otsubo , Yuji Ochi , Masami Nakai , Atsushi Mori
IPC分类号： C07D215/38
CPC分类号： C07D215/24 , A61K31/47 , A61K31/4704 , C07D215/233 , C07D215/40 , C07D401/04 , C07D405/04 , C07D407/04 , C07D409/04 , C07D413/04
摘要： The present invention provides a quinolone compound represented by General Formula (1) or a salt thereof, wherein R1 represents a hydrogen atom, etc.; R2 represents a hydrogen atom, etc.; R3 represents a phenyl group optionally being substituted with one or more substituents, etc.; R4 represents a halogen atom; R5 represents a hydrogen atom or halogen atom; R6 represents a hydrogen atom; and R7 represents a hydroxyl group, etc. The quinolone compound have a functional improvement effect, which suppresses progression of neurological dysfunction by inhibiting the chronic progression of Parkinson's disease or protecting dopamine neurons from the disease etiology, thereby prolonging the period before first administration begins.
摘要翻译： 本发明提供由通式（1）表示的喹诺酮化合物或其盐，其中R1表示氢原子等; R2表示氢原子等; R3表示任选被一个或多个取代基取代的苯基等; R4代表卤原子; R5表示氢原子或卤素原子; R6代表氢原子; 并且R7表示羟基等。喹诺酮化合物具有功能改善效果，通过抑制帕金森病的慢性进展或保护多巴胺神经元免受疾病病因抑制神经功能障碍的进展，从而延长第一次给药开始前的时期。
-
公开(公告)号：US08642619B2
公开(公告)日：2014-02-04
申请号：US13590227
申请日：2012-08-21
申请人： Kenji Otsubo , Yuji Ochi , Masami Nakai , Atsushi Mori
发明人： Kenji Otsubo , Yuji Ochi , Masami Nakai , Atsushi Mori
IPC分类号： A61K31/04 , C07D215/38
CPC分类号： C07D215/24 , A61K31/47 , A61K31/4704 , C07D215/233 , C07D215/40 , C07D401/04 , C07D405/04 , C07D407/04 , C07D409/04 , C07D413/04
摘要： The present invention provides a quinolone compound represented by General Formula (1) or a salt thereof, wherein R1 represents a hydrogen atom, etc.; R2 represents a hydrogen atom, etc.; R3 represents a phenyl group optionally being substituted with one or more substituents, etc.; R4 represents a halogen atom; R5 represents a hydrogen atom or halogen atom; R6 represents a hydrogen atom; and R7 represents a hydroxyl group, etc. The quinolone compound have a functional improvement effect, which suppresses progression of neurological dysfunction by inhibiting the chronic progression of Parkinson's disease or protecting dopamine neurons from the disease etiology, thereby prolonging the period before first administration begins.
摘要翻译： 本发明提供由通式（1）表示的喹诺酮化合物或其盐，其中R1表示氢原子等; R2表示氢原子等; R3表示任选被一个或多个取代基取代的苯基等; R4代表卤原子; R5表示氢原子或卤素原子; R6代表氢原子; 并且R7表示羟基等。喹诺酮化合物具有功能改善效果，通过抑制帕金森病的慢性进展或保护多巴胺神经元免受疾病病因抑制神经功能障碍的进展，从而延长第一次给药开始前的时期。
-
公开(公告)号：US20110251180A1
公开(公告)日：2011-10-13
申请号：US13128803
申请日：2009-12-04
申请人： Kenji Otsubo , Yuji Ochi , Masami Nakai , Atsushi Mori , Takayuki Matsuzaki
发明人： Kenji Otsubo , Yuji Ochi , Masami Nakai , Atsushi Mori , Takayuki Matsuzaki
IPC分类号： A61K31/47 , C07D215/22 , C07D215/233 , C07D401/04 , A61K31/4709 , C07D215/38 , C07D405/10 , C07D409/04 , C07D401/10 , C07D413/10 , A61K31/5377 , A61K31/496 , A61K31/55 , A61P25/00 , A61P9/10 , A61P1/16 , A61P37/02 , A61P9/00 , A61P3/10 , A61P11/00 , C07D215/26
CPC分类号： C07D409/04 , A61K31/47 , A61K31/4709 , A61K31/496 , A61K31/5377 , A61K31/55 , C07D215/233 , C07D215/26 , C07D215/36 , C07D215/38 , C07D215/40 , C07D215/48 , C07D401/04 , C07D405/04
摘要： The present invention provides a pharmaceutical agent that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the pharmaceutical agent of the invention comprising as an active ingredient a quinolone compound represented by Formula (1): or a salt thereof, wherein: R1 represents hydrogen or the like; R2 represents hydrogen or the like; R3 represents substituted or unsubstituted phenyl or the like; R4 represents hydrogen or the like; R5 represents hydrogen or the like; R6 represents hydrogen or the like; and R7 represents hydroxy or the like.
摘要翻译： 本发明提供抑制帕金森病慢性进展或保护多巴胺神经元免受疾病病因的药剂，从而抑制神经功能障碍的进展，从而延长使用L-多巴的时间，同时也改善神经元功能 ; 本发明的药剂包含作为活性成分的由式（1）表示的喹诺酮化合物或其盐，其中：R1表示氢等; R2表示氢等; R3表示取代或未取代的苯基等; R4表示氢等; R5表示氢等; R6表示氢等; 并且R 7表示羟基等。
-
公开(公告)号：US20100130546A1
公开(公告)日：2010-05-27
申请号：US12599003
申请日：2008-06-06
申请人： Kenji Otsubo , Yuji Ochi , Masami Nakai , Atsushi Mori
发明人： Kenji Otsubo , Yuji Ochi , Masami Nakai , Atsushi Mori
IPC分类号： A61K31/4709 , C07D215/26 , A61P25/16 , A61P25/28 , A61P25/00 , A61P3/00 , A61P27/00
CPC分类号： C07D215/24 , A61K31/47 , A61K31/4704 , C07D215/233 , C07D215/40 , C07D401/04 , C07D405/04 , C07D407/04 , C07D409/04 , C07D413/04
摘要： The present invention provides a quinolone compound represented by General Formula (1) or a salt thereof, wherein R1 represents a hydrogen atom, etc.; R2 represents a hydrogen atom, etc.; R3 represents a phenyl group optionally being substituted with one or more substituents, etc.; R4 represents a halogen atom; R5 represents a hydrogen atom or halogen atom; R6 represents a hydrogen atom; and R7 represents a hydroxyl group, etc. The quinolone compound have a functional improvement effect, which suppresses progression of neurological dysfunction by inhibiting the chronic progression of Parkinson's disease or protecting dopamine neurons from the disease etiology, thereby prolonging the period before first administration begins.
摘要翻译： 本发明提供由通式（1）表示的喹诺酮化合物或其盐，其中R1表示氢原子等; R2表示氢原子等; R3表示任选被一个或多个取代基取代的苯基等; R4代表卤原子; R5表示氢原子或卤素原子; R6代表氢原子; 并且R7表示羟基等。喹诺酮化合物具有功能改善效果，通过抑制帕金森病的慢性进展或保护多巴胺神经元免受疾病病因抑制神经功能障碍的进展，从而延长第一次给药开始前的时期。
-
公开(公告)号：US20060102327A1
公开(公告)日：2006-05-18
申请号：US10534016
申请日：2003-11-12
申请人： Masahiro Inui , Kaoru Hamada , Kenji Otsubo
发明人： Masahiro Inui , Kaoru Hamada , Kenji Otsubo
CPC分类号： F28F1/40 , B01F2005/0626 , B01F2005/0636 , B01J19/006 , B01J19/2415 , C10G9/20 , F28D2021/0022
摘要： A cracking tube (50) for use in thermal cracking furnaces for producing ethylene or the like has fins (1) formed on an inner surface thereof and inclined with respect to an axis of the tube for stirring a fluid inside the tube. The fins are arranged discretely on one or a plurality of helical loci, and the tube inner surface has regions (ZB) wherein no fins are present over the entire axial length of the tube from one axial end of the tube to the other axial end thereof.
摘要翻译： 用于生产乙烯等的热裂解炉的裂解管（50）在其内表面上形成有相对于管轴倾斜的翅片（1），用于搅拌管内的流体。 翅片离散地布置在一个或多个螺旋轨迹上，并且管内表面具有区域（ZBB），其中在管的整个轴向长度上不存在翅片， 管到另一个轴向端。
-
公开(公告)号：US07799963B2
公开(公告)日：2010-09-21
申请号：US12379845
申请日：2009-03-03
申请人： Masahiro Inui , Kaoru Hamada , Kenji Otsubo
发明人： Masahiro Inui , Kaoru Hamada , Kenji Otsubo
CPC分类号： F28F1/40 , B01F2005/0626 , B01F2005/0636 , B01J19/006 , B01J19/2415 , C10G9/20 , F28D2021/0022
摘要： A cracking tube (50) for use in thermal cracking furnaces for producing ethylene or the like has fins (1) formed on an inner surface thereof and inclined with respect to an axis of the tube for stirring a fluid inside the tube. The fins are arranged discretely on one or a plurality of helical loci, and the tube inner surface has regions (ZB) wherein no fins are present over the entire axial length of the tube from one axial end of the tube to the other axial end thereof.
摘要翻译： 用于生产乙烯等的热裂解炉的裂解管（50）在其内表面上形成有相对于管轴倾斜的翅片（1），用于搅拌管内的流体。 翅片离散设置在一个或多个螺旋轨迹上，并且管内表面具有区域（ZB），其中在管的整个轴向长度上从管的一个轴向端到另一个轴向端都不存在翅片 。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.027 秒)
